H.C. Wainwright analyst Oren Livnat reiterated a Neutral rating on Verrica Pharmaceuticals (NASDAQ: VRCA).The analyst commented: "Yesterday, Verrica preannounced 1Q25 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE